Aktienanalyse zu Prothena Corporation PLC (PRTA)PRTAProthena Corporation PLC

Prothena Corporation plc is an Ireland-based late-stage clinical biotechnology company. The Company is engaged in protein dysregulation and a pipeline of investigational therapeutics for rare peripheral amyloid diseases. The Company is advancing a pipeline of therapeutic candidates for a range of indications and targets to integrate scientific insights around neurological dysfunction and the biology of misfolded proteins. The Company’s pipeline includes both wholly owned and partnered programs being developed for the potential treatment of diseases, including AL amyloidosis, ATTR amyloidosis, Alzheimer’s disease, Parkinson’s disease and a range of other neurodegenerative diseases. Its clinical programs include birtamimab for the potential treatment of AL amyloidosis, prasinezumab for the potential treatment of Parkinson’s disease, NNC6019/PRX004 for the potential treatment of ATTR amyloidosis, and PRX005 and PRX012 for the potential treatment of Alzheimer’s disease. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Prothena Corporation PLC (PRTA) is currently not a strong buy due to its recent performance and technical indicators. The current price is $8.35, which is significantly lower than the analyst price target of $20, indicating potential upside. However, the RSI is at 44.158, suggesting that the stock is nearing oversold territory but has not yet reached it. The stock has a forward P/E of 10.627, which is reasonable, but the recent 1-year change of -19.48% raises concerns about its performance. The main risk is the negative net income reported in the last quarter, which was -18,583,000 USD, indicating ongoing financial challenges. Therefore, while there is potential for recovery, the current indicators suggest holding rather than buying.

12 analysts cover PRTA: 12 rate it Buy, 0 Hold and 0 Sell. The average price target is 22.20.